Department of Anesthesiology. Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
Tehran University of Medical Sciences, Tehran, IR Iran
Department of Anesthesiology. Children's Medical Center, Tehran University of Medical Sciences, Tehran, IR Iran
Background: Providing and maintaining normovolemic condition during major surgeries is a major
challenge, especially in children. In this respect, third-generation hydroxyethyl starches seem to
be more cost-effective than human albumin. However, the efficacy of 6% hydroxyethyl starch
(HES) 130/0.4 compared to other alternatives such as human albumin 5% remains uncertain in
The present study aimed to assess the efficacy and safety of replacing human albumin 5% with
6% HES 130/0.4 for volume replacement therapy in children undergoing selective open cardiac
Method: This randomized double-blinded clinical trial was performed on 59 children aged less than 2
years and ASA I-III who were candidated for selective open-heart surgery and referred to a
children medical center in 2014. The patients were randomly assigned via the block
randomization method to the case group (n = 30) receiving a solution of 6% HES 130/0.4 and
the control group (n = 29) receiving 5% human albumin.
There were no between-group differences in hemodynamic parameters—including pulse rate,
systolic and diastolic blood pressures, and mean blood pressure—at the time points of before
anesthesia induction, before and after pump insertion, and 24 hours after surgery.
Results: Comparisons of the laboratory indices indicated no differences between the 2 groups at the
different time points. The volume of packed cell and colloid fluids infused in the case and
control group was also similar.
Conclusions: Compared to human albumin 5%, 6% HES 130/0.4 is a safe alternative to fluid supply
during cardiac surgery among children.